DIA global headquarters will host 18 leaders from the State Food and Drug Administration of China (SFDA). The SFDA delegation is comprised of leaders from different provinces of China as well as four individuals from the central office in Beijing. Their expertise includes drug registration and the center of control testing labs.
Prior to their arrival at DIA, the group participated in a 10-day regulatory affairs training at Yale University’s School of Public Health. Since completing the program earlier this week, the delegation has been visiting various organizations such as the NJ FDA Field Office, Novartis, the University of Sciences Philadelphia, and the United States Pharmacopeia (USP). SFDA participants include:
“DIA is a global community that shares knowledge, cultivates relationships, and facilitates dialogue among regulators across and within all geographic regions,” says Paul Pomerantz, DIA Worldwide Executive Director.” We are pleased to welcome representatives from SFDA to our global headquarters to explore how our organizations can continue to work together to educate our industry about reporting, compliance and other requirements and developments around the world.”
In addition, three executive team members from the Sino-American Pharmaceutical Professionals Association of Greater Philadelphia (SAPA GP) will be in attendance.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.